Skip to main content

Table 3 Effect of biologic therapy on rheumatoid arthritis progression

From: The loss of health status in rheumatoid arthritis and the effect of biologic therapy: a longitudinal observational study

Variable N Pre biologic therapy
Rate (95% CI)
Post biologic therapy
Rate (95% CI)
Rate difference
Rate (95% CI)
HAQ (all) 4,911 0.032 (0.027, 0.036) 0.003 (0.000, 0.006) -0.029 (-0.023, -0.034)
HAQ (on) 3,829 0.031 (0.026, 0.036) -0.001 (-0.004, 0.002) -0.033 (-0.026, -0.039)
HAQ (DC) 1,082 0.033 (0.021, 0.044) 0.013 (0.008, 0.017) 0.020 (0.007, 0.033)
PCS (all) 4,911 -0.353 (-0.432, -0.273) 0.179 (0.129, 0.229) -0.532 (-0.634, -0.430)
PCS (on) 3,829 -0.348 (-0.436, -0.260) 0.261 (0.198, 0.323) -0.608 (-0.725, -0.491)
PCS (DC) 1,082 -0.396 (-0.591, -0.201) -0.003 (-0.082, 0.075) -0.393 (-0.619, -0.166)
MCS (all) 4,911 -0.096 (-0.176, -0.016) 0.000 (-0.056, 0.057) -0.096 (-0.197, 0.005)
MCS (on) 3,829 -0.124 (-0.211, -0.037) 0.052 (-0.012, 0.116) -0.176 (-0.289, -0.063)
MCS (DC) 1,082 0.015 (-0.083, 0.212) -0.117 (-0.226, -0.008) 0.132 (-0.104, 0.368)
EQ-5D (all) 3,997 -0.003 (-0.005, -0.000) 0.002 (0.001, 0.003) -0.005 (-0.008, -0.002)
EQ-5D (on) 3,031 -0.003 (-0.006, 0.000) 0.003 (0.002, 0.004) -0.006 (-0.009, -0.002)
EQ-5D (DC) 966 -0.001 (-0.007, 0.004) -0.001 (-0.003, 0.002) -0.001 (-0.007, 0.006)
All patients   Pre biologic therapy
Mean (95% CI)
Post biologic therapy
Mean (95% CI)
Cost difference
Mean (95% CI)
Total Costs 4,911 $8,454 (8,140, 8,769) $24,369 (21,172, 24,565) $15,914 (15,543, 16,285)
Drug Costs 4,911 $4,681 (4,401, 4,961) $20,401 (20,226, 20,576) $15,720 (15,390, 16,051)
Variable N Estimated scores
Time = -10 years
Mean (95% CI)
Actual scores
Time = 0 years
Mean (95% CI)
Estimated scores
Time = +10 years
Mean (95% CI)
HAQ 4,911 1.02 (0.99, 1.05) 1.13 (1.11, 1.15) 1.24 (1.21, 1.27)
PCS 4,911 35.2 (34.7, 35.6) 35.4 (35.1, 25.7) 35.7 (35.2, 36.1)
MCS 4,911 50.2 (49.8, 50.7) 49.8 (49.5, 50.1) 49.3 (48.9, 49.8)
EQ-5D 3,997 0.721 (0.709, 0.733) 0.730 (0.724, 0.736) 0.740 (0.730, 0.749)
  1. Effect of biologic therapy on annual rates of progression of disability, loss of health status, and costs in patients prior to and after the start of biologic therapy in RA.
  2. All, all patients; on, on biologics at study close; DC, discontinued biologic before study close.
  3. Positive rates indicate worsening HAQ disability. Negative rates indicate worsening health status for MCS, PCS, and EQ-5D. A negative rate difference indicates improvement. Times are relative to biologic therapy initiation.
  4. HAQ, Health Assessment Questionnaire; PCS, SF-36 Physical Component Summary; MCS, SF-36 Mental Component Summary.